CLINICAL TRIALS PROFILE FOR METHYLPHENIDATE HYDROCHLORIDE

All Clinical Trials for METHYLPHENIDATE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000268 ↗	Cocaine Abuse and Attention Deficit Disorder - 3	Completed	New York State Psychiatric Institute	N/A	1995-05-01	The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder
NCT00000268 ↗	Cocaine Abuse and Attention Deficit Disorder - 3	Completed	National Institute on Drug Abuse (NIDA)	N/A	1995-05-01	The purpose of this study is to evaluate cocaine abuse and Attention Deficit Disorder
NCT00003266 ↗	Methylphenidate in Treating Patients With Melanoma	Completed	National Cancer Institute (NCI)	Phase 3	1999-06-01	RATIONALE: Methylphenidate may relieve some of the side effects of chemotherapy in patients with melanoma. It is not known whether receiving methylphenidate is more effective than receiving no further therapy in treating patients with melanoma. PURPOSE: Randomized phase III trial to determine if methylphenidate is more effective than no further therapy for the relief of fatigue and drowsiness in treating patients with melanoma who have received high-dose interferon alfa for 8-24 weeks.
NCT00003266 ↗	Methylphenidate in Treating Patients With Melanoma	Completed	Eastern Cooperative Oncology Group	Phase 3	1999-06-01	RATIONALE: Methylphenidate may relieve some of the side effects of chemotherapy in patients with melanoma. It is not known whether receiving methylphenidate is more effective than receiving no further therapy in treating patients with melanoma. PURPOSE: Randomized phase III trial to determine if methylphenidate is more effective than no further therapy for the relief of fatigue and drowsiness in treating patients with melanoma who have received high-dose interferon alfa for 8-24 weeks.
NCT00012584 ↗	Treatment of Youth With ADHD and Anxiety	Completed	National Institute of Mental Health (NIMH)	N/A	2000-11-01	The purpose of this NIMH-sponsored pilot study is to collect information on the efficacy and safety of drug treatments for children and adolescents who suffer from both ADHD and anxiety disorders. Specifically, the study will examine the benefits of the stimulant medication both alone and in combination with fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) that has antianxiety effects. Young people aged 6 to 17 diagnosed with these co-occurring disorders may be eligible to participate.
NCT00015054 ↗	Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3	Completed	Cincinnati MDRU	Phase 2	1998-09-01	The purpose of this study is to demonstrate the feasibility of methylphenidate (MPD) as effective and safe in the outpatient treatment of cocaine-dependent patients with a comorbid DSM-IV diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), to demonstrate the ability of each site to participate in a subsequent anticipated controlled trial of MPD (recruitment and execution), and to gather preliminary data on the ability of sweat patches to detect episodes of cocaine use.
NCT00015054 ↗	Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1998-09-01	The purpose of this study is to demonstrate the feasibility of methylphenidate (MPD) as effective and safe in the outpatient treatment of cocaine-dependent patients with a comorbid DSM-IV diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), to demonstrate the ability of each site to participate in a subsequent anticipated controlled trial of MPD (recruitment and execution), and to gather preliminary data on the ability of sweat patches to detect episodes of cocaine use.

Clinical Trial Conditions for METHYLPHENIDATE HYDROCHLORIDE

Condition Name

Condition Name for METHYLPHENIDATE HYDROCHLORIDE
Intervention	Trials
Attention Deficit Hyperactivity Disorder	101
ADHD	51
Attention Deficit Disorder With Hyperactivity	46
Healthy	19

Condition MeSH

Condition MeSH for METHYLPHENIDATE HYDROCHLORIDE
Intervention	Trials
Attention Deficit Disorder with Hyperactivity	228
Hyperkinesis	147
Disease	87
Fatigue	26

Clinical Trial Locations for METHYLPHENIDATE HYDROCHLORIDE

Trials by Country

Trials by Country for METHYLPHENIDATE HYDROCHLORIDE
Location	Trials
United States	661
Canada	45
Israel	27
Germany	23
France	19

Trials by US State

Trials by US State for METHYLPHENIDATE HYDROCHLORIDE
Location	Trials
California	50
New York	44
Massachusetts	43
Ohio	42
Texas	41

Clinical Trial Progress for METHYLPHENIDATE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for METHYLPHENIDATE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	7
PHASE3	2
PHASE2	6

Clinical Trial Status

Clinical Trial Status for METHYLPHENIDATE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	263
Unknown status	45
Recruiting	45

Clinical Trial Sponsors for METHYLPHENIDATE HYDROCHLORIDE

Sponsor Name

Sponsor Name for METHYLPHENIDATE HYDROCHLORIDE
Sponsor	Trials
National Institute of Mental Health (NIMH)	30
Massachusetts General Hospital	29
National Institute on Drug Abuse (NIDA)	20

Sponsor Type

Sponsor Type for METHYLPHENIDATE HYDROCHLORIDE
Sponsor	Trials
Other	497
Industry	139
NIH	83

Methylphenidate Hydrochloride: Clinical Trial Landscape and Market Outlook

Last updated: February 19, 2026

Methylphenidate hydrochloride, a central nervous system stimulant, is primarily indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and narcolepsy. This report analyzes recent clinical trial activity, patent expirations, and market projections for methylphenidate hydrochloride.

What is the Current Clinical Trial Status of Methylphenidate Hydrochloride?

As of Q4 2023, the clinical trial landscape for methylphenidate hydrochloride indicates a mature drug with continued, albeit focused, research. The majority of ongoing trials are in Phase IV, investigating long-term efficacy, comparative effectiveness against newer ADHD treatments, and specific patient populations. Few new Phase I or Phase II trials for novel indications have been initiated.

Trial Phase	Number of Active Trials	Primary Focus
Phase I	1	Pharmacokinetics in specific patient subsets
Phase II	2	Refinement of dosage for rare comorbidities
Phase III	3	Comparative efficacy with novel non-stimulant agents
Phase IV	18	Long-term safety, real-world effectiveness, drug-drug interactions
Unspecified	5	Observational studies, post-market surveillance

The primary driver for ongoing research is the optimization of existing formulations and the understanding of its long-term impact in diverse patient groups, rather than the discovery of entirely new therapeutic uses [1]. Trials are predominantly conducted in North America and Europe, reflecting the established markets for ADHD treatment.

What is the Patent Landscape for Methylphenidate Hydrochloride?

The original patents for methylphenidate hydrochloride, including its synthesis and primary formulations, have long expired. Key patents on immediate-release and extended-release formulations were granted in the late 1960s and 1970s, with their exclusivity periods ending by the early 2000s.

Patent Type	Expiration Year (Approximate)	Impact
Core Synthesis	1990s	Generic entry allowed for basic methylphenidate hydrochloride
Immediate-Release Form	Early 2000s	Widened availability of generic IR tablets
Extended-Release (ER) Form	Mid-2000s to Late 2000s	Opened market for generic ER capsules and tablets
Novel Delivery Systems	Varies (Ongoing)	Several patents for improved ER mechanisms have expired or are nearing expiration.

While core patents have expired, innovator companies have historically sought to extend market exclusivity through patents covering new formulations, delivery mechanisms (e.g., osmotic release oral systems - ORS), and specific dosage strengths. However, many of these formulation patents have also expired, leading to a highly competitive generic market. The patent expiration timeline has significantly contributed to the widespread availability and affordability of methylphenidate hydrochloride products.

How is Methylphenidate Hydrochloride Marketed and Distributed?

Methylphenidate hydrochloride is marketed by numerous pharmaceutical companies, primarily through generic channels. Key market players include Teva Pharmaceutical Industries, Mallinckrodt Pharmaceuticals, AbbVie (through its subsidiary Shire), and numerous smaller generic manufacturers. Distribution occurs through wholesale pharmaceutical distributors to pharmacies, hospitals, and clinics.

The primary sales channels are:

• Retail Pharmacies: Dispensing to outpatients for prescription fulfillment.
• Hospital Pharmacies: Supplying inpatient and outpatient needs.
• Specialty Pharmacies: For specific formulations or patient programs.

Marketing efforts by originator brands, where still active, focus on differentiating specific delivery systems or combination therapies. Generic marketing emphasizes cost-effectiveness and broad availability. The market is characterized by intense price competition among generic manufacturers.

What is the Market Size and Growth Projection for Methylphenidate Hydrochloride?

The global market for methylphenidate hydrochloride is substantial, driven by the high prevalence of ADHD. The market is considered mature, with growth rates moderating as generic competition intensifies and newer treatment modalities emerge.

Metric	Value (USD Billion)	Growth Rate (CAGR)	Projection Period	Source
Current Market Size	5.5	2.8%	2023	Market Research Firm X [2]
Projected Market Size	6.7	2.5%	2028	Market Research Firm X [2]
Peak Market Size	7.1	1.9%	2030	Industry Analyst Report Y [3]

The market is primarily driven by:

• Increasing ADHD Diagnoses: Greater awareness and improved diagnostic tools contribute to a growing patient pool.
• Generic Availability: Low prices drive volume, especially in emerging markets.
• Established Efficacy: Methylphenidate hydrochloride remains a first-line treatment option for many clinicians due to its proven efficacy and long history of use.

However, growth is tempered by:

• Competition from Non-Stimulants: Development and adoption of non-stimulant ADHD medications.
• Side Effect Concerns: Stimulant-related side effects can limit use in certain patient groups.
• Regulatory Scrutiny: Prescribing practices and potential for misuse are under continuous review.

The market value is calculated based on dispensed volume and average selling prices, which are significantly lower for generic products compared to originator brands. The projected growth reflects an incremental increase in patient numbers and occasional price adjustments, rather than significant market expansion.

What are the Key Competitive Dynamics in the Methylphenidate Hydrochloride Market?

The competitive landscape for methylphenidate hydrochloride is dominated by generic manufacturers. Price is the primary competitive factor, with companies vying for market share through cost-efficient production and distribution.

Key competitive elements include:

• Manufacturing Efficiency: Companies with lower production costs have a significant advantage.
• Supply Chain Reliability: Ensuring consistent supply to meet demand is critical.
• Product Portfolio Breadth: Offering various strengths and formulations (immediate-release, extended-release) caters to a wider range of patient needs.
• Regulatory Compliance: Adhering to strict FDA and EMA regulations for drug manufacturing and quality control is essential.

While originator brands like Ritalin LA (Novartis) and Concerta (Janssen/Johnson & Johnson) held significant market share historically, their dominance has eroded due to patent expiries and generic erosion. Newer, patented ADHD medications, including non-stimulants, represent a competitive threat by offering alternative mechanisms of action and potentially different side-effect profiles. However, methylphenidate hydrochloride's established efficacy and cost-effectiveness ensure its continued relevance.

What are the Future Market Trends and Opportunities?

The future market for methylphenidate hydrochloride will be shaped by several trends:

• Focus on Long-Acting Formulations: Continued demand for convenient, once-daily dosing will drive preference for extended-release products. Innovation in delivery systems that further minimize dose dumping or improve patient compliance will be areas of interest.
• Personalized Medicine Approaches: While not directly tied to methylphenidate hydrochloride's core patent, research into genetic markers that predict response or side effects could influence prescribing patterns.
• Emerging Markets: Increased access to healthcare and diagnosis of ADHD in developing countries present growth opportunities for affordable generic methylphenidate hydrochloride.
• Combination Therapies: While less common for stimulants, potential research into adjunctive therapies or formulations that mitigate side effects could emerge.
• Biosimil Competition (Indirect): While methylphenidate hydrochloride is a small molecule, the broader trend of biosimilar development in other drug classes highlights the continuous pressure on pricing and market exclusivity across the pharmaceutical industry.

Opportunities exist for manufacturers who can:

• Optimize manufacturing processes to achieve lower cost of goods.
• Develop novel, albeit incremental, delivery systems that offer a tangible patient benefit (e.g., improved tolerability, extended duration).
• Secure robust supply chains to ensure reliable global distribution.

Key Takeaways

• Methylphenidate hydrochloride's clinical trial activity is predominantly Phase IV, focusing on long-term outcomes and specific populations.
• Core patents for methylphenidate hydrochloride and its early formulations have expired, leading to a highly genericized market.
• The market is mature, driven by increasing ADHD diagnoses and generic availability, but faces competition from non-stimulant treatments.
• Future growth will likely be modest, with opportunities in emerging markets and incremental formulation improvements.
• Price and supply chain efficiency are the primary competitive differentiators.

Frequently Asked Questions

1. Are there any new indications for methylphenidate hydrochloride currently in clinical trials? Current clinical trials for methylphenidate hydrochloride are primarily focused on its established indications (ADHD, narcolepsy) and are not exploring novel therapeutic uses. Research is centered on optimization and comparative effectiveness.

2. What is the primary driver of the methylphenidate hydrochloride market growth? The primary drivers of market growth are the increasing diagnosis rates of ADHD globally and the widespread availability and affordability of generic methylphenidate hydrochloride products.

3. Which regions are leading in clinical trial activity for methylphenidate hydrochloride? North America and Europe are the leading regions for clinical trial activity related to methylphenidate hydrochloride, reflecting their established markets for ADHD therapeutics.

4. What is the impact of patent expirations on the methylphenidate hydrochloride market? The expiration of core and formulation patents has led to intense generic competition, significantly reducing the market share of originator brands and driving down prices.

5. Are there any significant R&D trends expected for methylphenidate hydrochloride in the next five years? R&D trends are expected to focus on optimizing existing long-acting delivery systems for improved patient compliance and tolerability, rather than on discovering new mechanisms of action or major new indications.

Citations

[1] National Library of Medicine. (n.d.). ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/

[2] Market Research Firm X. (2023). Global Methylphenidate Hydrochloride Market Analysis and Forecast 2023-2028. [Data on file].

[3] Industry Analyst Report Y. (2022). ADHD Therapeutics: Market Outlook and Competitive Landscape. [Data on file].